Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 03/27/24
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of DirectorsGlobeNewsWire • 03/26/24
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker PatientsGlobeNewsWire • 03/06/24
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker PatientsGlobeNewsWire • 01/08/24
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/13/23
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker PatientsGlobeNewsWire • 09/19/23
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent RestenosisGlobeNewsWire • 08/08/23
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial OfficerGlobeNewsWire • 06/07/23
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/23
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023GlobeNewsWire • 02/24/23